Blog
RSS FeedPosted by Michael Wonder on 03 Aug 2016
Ramucirumab in gastric cancer: no sign of an additional clinical benefit
1 August 2016 - Former orphan drug undergoes regular early benefit assessment; submitted studies unsuitable for assessment. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in advanced lung cancer: evidence for significant additional benefits
1 August 2016 - Advantages in overall survival and side effects. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in renal cell carcinoma: indication of additional clinical benefits
1 August 2016 - Benefits in overall survival, morbidity and side effects. ...
Posted by Michael Wonder on 02 Aug 2016
Ospemifene in vulvovaginal atrophy: additional clinical benefits not seen says IQWiG
1 August 2016 - Incorrect study population, studies were too short. ...
Posted by Michael Wonder on 02 Jul 2016
Idelalisib in the second-line treatment in CLL: additional benefits still not seen
1 July 2016 - EMA safety review invokes reassessment but still no relevant data. ...
Posted by Michael Wonder on 02 Jul 2016
Ticagrelor prevention after myocardial infarction: little additional benefit
1 June 2016 - The IQWIG has re-examined the benefits of the use of ticagrelor (Brilique) after acute coronary syndrome. ...
Posted by Michael Wonder on 16 Jun 2016
Sacubitril with valsartan in heart failure: differentiated value added
16 June 2016 - Addendum results in a revised benefit assessment for patients with type 2 diabetes mellitus. ...
Posted by Michael Wonder on 15 Jun 2016
Osimertinib mesylate in lung cancer: no assigned additional benefits
15 June 2016 - No direct comparative studies / effects in historical comparisons too small for statements for additional benefits. ...
Posted by Michael Wonder on 02 Jun 2016
Cobimetinib in advanced melanoma with BRAF V600 mutation: added benefit now considerable
2 June 2016 - New analyses from the commenting procedure showed further advantages of the drug. ...
Posted by Michael Wonder on 01 Jun 2016
Ramucirumab in colorectal and lung cancer: some additional benefits, some reductions in benefits
1 June 2016 - Germany's IQWiG has just completed its assessment of Lilly's Cyramza for patients with colorectal cancer or ...
Posted by Michael Wonder on 17 May 2016
Brivaracetam in epilepsy: additional benefits not seen by IQWiG
17 May 2016 - No directly comparative study; the indirect comparisons are unusable. ...
Posted by Michael Wonder on 17 May 2016
Vismodegib for basal cell carcinoma: additional benefits still not seen says Germany's IQWiG
17 May 2016 - Submitted data deemed to be unsuitable. ...
Posted by Michael Wonder on 02 May 2016
Ibrutinib: indication of an additional clinical benefit in one of three therapeutic indications
2 May 2016 - The IQWIG in Germany has found ibrutinib has an additional clinical benefit for certain patients with ...
Posted by Michael Wonder on 02 May 2016
Umeclidinium for symptom relief in COPD: additional benefit is not proven
2 May 2016 - No sighificant differences for moderate disease and no data for severe disease. ...
Posted by Michael Wonder on 02 May 2016
Mepolizumab in severe asthma: additional benefit is not proven
2 May 2016 - Appropriate comparator therapy not implemented so the indirect comparison is unsuitable. ...